Akari Therapeutics (NASDAQ:AKTX) Stock Price Crosses Below 200-Day Moving Average – Here’s Why

Akari Therapeutics, Plc (NASDAQ:AKTX)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.24 and traded as low as $1.06. Akari Therapeutics shares last traded at $1.09, with a volume of 37,485 shares.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of Akari Therapeutics in a report on Friday. They set a “sell” rating for the company.

Akari Therapeutics Stock Down 0.3 %

The stock has a fifty day moving average of $1.15 and a two-hundred day moving average of $2.23.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.